Real-World Use of Adjuvant Nivolumab in Patients With Upper Gastrointestinal Cancer in Canada

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Upper Gastrointestinal Cancer

Treatments: Drug: Nivolumab

Study type: Observational

Funder types: Industry

Identifiers

NCT06361563

CA209-1442

Details and patient eligibility

About

The purpose of this observational study is to describe the patient, disease and treatment characteristics of eligible participants with upper gastrointestinal cancer treated with adjuvant nivolumab.

Enrollment: 250 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Enrolled in Bristol-Myers Squibb GastroEsophageal Opdivo in Resected Patients with Residual Pathological Disease Patient Support Program (GEORge PSP) in Canada
• Patients who have consented to the use of their de-identified data generated from information collected in the course of the GEORge PSP

Exclusion criteria

• Aged <18 years
• Did not receive concurrent chemoradiotherapy prior to surgery
• Positive margins following resection
• No residual disease following complete resection

Trial design

250 participants in 1 patient group

Participants treated with adjuvant nivolumab

Treatment:

Drug: Nivolumab